

## CLAIMS

The listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously Amended) A method of blocking an immune response to a foreign graft in a mammal, where the mammal is not suffering from a malignancy, comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.
- 2-4. (Cancelled)
5. (Original) The method of claim 1 wherein the mammal is human.
6. (Previously Amended) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.
7. (Previously Amended) The method of claim 1 wherein the antibody comprises rituximab.
8. (Previously Amended) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.
9. (Original) The method of claim 8 wherein the cytotoxic agent is a radioactive compound.
10. (Previously Amended) The method of claim 9 wherein the antibody comprises Y2B8 or <sup>131</sup>I-B1.
11. (Previously Amended) The method of claim 1 comprising administering the antibody intravenously.

12. (Previously Amended) The method of claim 1 comprising administering the antibody subcutaneously.

13. (Currently Amended) The method of claim 1, comprising administering a dose of ~~substantially~~ from about 20mg/m<sup>2</sup> to less than 375mg/m<sup>2</sup> of the antibody to the mammal.

14. (Original) The method of claim 13 wherein the dose is in the range from about 20mg/m<sup>2</sup> to about 250mg/m<sup>2</sup>.

15. (Original) The method of claim 14 wherein the dose is in the range from about 50mg/m<sup>2</sup> to about 200mg/m<sup>2</sup>.

16. (Previously Amended) The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m<sup>2</sup> dose of the antibody in the subsequent dose exceeds the mg/m<sup>2</sup> dose of the antibody in the initial dose.

17-21. (Cancelled)

22. (Previously Amended) The method of claim 1 comprising administering the antibody to the mammal before the mammal is exposed to the graft.

23-27. (Cancelled)

28. (Previously Amended) A method of treating graft-versus-host or host-versus-graft disease in a mammal comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.

29-31. (Cancelled)